摘要
目的 检测原发性肝癌组织中CD117、C-erbB-2及表皮生长因子受体(EGFR)表达,探讨其在肝癌诊断和治疗中的意义.方法 经病理确诊的127例原发性肝癌患者,采用免疫组织化学法检测肿瘤组织中CD117、C-erbB-2及EGFR表达,分析其与肿瘤数目、直径、血管侵犯、组织分化及甲胎蛋白(AFP)水平关系.结果 CD117、C-erbB-2及EGFR阳性表达率分别为32.3%(41/127)、22.8%(29/127)和27.6%(35/127),CD117表达与肿瘤数目、直径和血管侵犯明显相关;C-erbB-2表达与肿瘤直径、血管侵犯和肿瘤分化明显相关;EGFR表达与肿瘤数目、AFP水平和肿瘤分化明显相关.结论 肝癌组织表达CD117、C-erbB-2及EGFR与肿瘤形态和生物学特性有关,对肝癌预后判断和靶向治疗具有一定指导意义.
Objective To investigate the expression of CD117,C-erbB-2 and epidermal growth factor receptor (EGFR) in primary hepatocellular carcinoma (HCC) tissue and their diagnostic and therapeutic significance.Methods The expression of CD117,C-erbB-2 and EGFR in 127 cases of HCC tissues was detected by using immunohistochemstry.The relationship of their positive staining rate with tumor number,size,vascular invasion,tissue differentiation and alpha fetoprotein (AFP) level was analyzed.Results The positive staining rate of CD117,C-erbB-2 and EGFR in HCC tissue was 32.3% (41/127),22.8% (29/127) and 27.6% ( 35/127),respectively.The expression of CD117 was significantly associated with patients' tumor number,size and vascular invasion,while C-erbB-2 with tumor size,vascular invasion and tissue differentiation,and EGFR with tumor size,AFP level and tissue differentiation.Conclusion The expression of CD117,C-erbB-2 and EGFR in HCC tissue had some relationship with tumor morphological and biological characteristics,which may help predict the prognosis of HCC and prescribe target therapy in future.
出处
《中华实验外科杂志》
CAS
CSCD
北大核心
2010年第12期1815-1817,共3页
Chinese Journal of Experimental Surgery